[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800-466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 58, "title": "Executive VP, CFO & COO", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 658230, "exercisedValue": 0, "unexercisedValue": 73311}, {"maxAge": 1, "name": "Ms. Laura  Kavanaugh", "title": "VP & Head of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "age": 47, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kieron  Wesson Ph.D.", "title": "Vice President & Head of Chemistry Manufacturing Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.84, "open": 9.88, "dayLow": 9.3883, "dayHigh": 10.8331, "regularMarketPreviousClose": 9.84, "regularMarketOpen": 9.88, "regularMarketDayLow": 9.3883, "regularMarketDayHigh": 10.8331, "payoutRatio": 0.0, "beta": 2.775, "forwardPE": -0.85570467, "volume": 112411, "regularMarketVolume": 112411, "averageVolume": 96809, "averageVolume10days": 72240, "averageDailyVolume10Day": 72240, "bid": 7.38, "ask": 12.6, "bidSize": 2, "askSize": 2, "marketCap": 70903976, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 22.338997, "fiftyDayAverage": 8.175, "twoHundredDayAverage": 15.229775, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -53322984, "profitMargins": 0.0, "floatShares": 3001994, "sharesOutstanding": 6151370, "sharesShort": 361738, "sharesShortPriorMonth": 533025, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.051999997, "heldPercentInsiders": 0.1037, "heldPercentInstitutions": 0.54158, "shortRatio": 4.5, "shortPercentOfFloat": 0.059899997, "impliedSharesOutstanding": 6951370, "bookValue": 16.56, "priceToBook": 0.61594206, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -74184000, "trailingEps": -13.27, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -16.8, "enterpriseToEbitda": 0.687, "52WeekChange": -0.23652697, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 10.2, "targetHighPrice": 175.0, "targetLowPrice": 36.0, "targetMeanPrice": 80.25, "targetMedianPrice": 55.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 122945000, "totalCashPerShare": 19.987, "ebitda": -77562000, "totalDebt": 6878000, "quickRatio": 6.067, "currentRatio": 6.314, "totalRevenue": 3174000, "debtToEquity": 6.752, "revenuePerShare": 0.405, "returnOnAssets": -0.40297002, "returnOnEquity": -0.87741995, "grossProfits": -58109000, "freeCashflow": -44316000, "operatingCashflow": -74917000, "revenueGrowth": -0.09, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -19.24041, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "regularMarketChangePercent": 3.65853, "regularMarketPrice": 10.2, "corporateActions": [], "postMarketTime": 1755895124, "regularMarketTime": 1755892801, "marketState": "CLOSED", "postMarketPrice": 10.2, "postMarketChange": 0.0, "regularMarketChange": 0.36, "regularMarketDayRange": "9.3883 - 10.8331", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 96809, "fiftyTwoWeekLowChange": 6.4399996, "fiftyTwoWeekLowChangePercent": 1.7127658, "fiftyTwoWeekRange": "3.76 - 46.8", "fiftyTwoWeekHighChange": -36.6, "fiftyTwoWeekHighChangePercent": -0.78205127, "fiftyTwoWeekChangePercent": -23.652697, "earningsTimestamp": 1754510400, "earningsTimestampStart": 1762372800, "earningsTimestampEnd": 1762372800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -13.27, "epsForward": -11.92, "epsCurrentYear": -7.88, "priceEpsCurrentYear": -1.2944162, "fiftyDayAverageChange": 2.0249996, "fiftyDayAverageChangePercent": 0.24770637, "twoHundredDayAverageChange": -5.0297756, "twoHundredDayAverageChangePercent": -0.33025935, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "postMarketChangePercent": 0.0, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]